Patrick Jimonet

New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.

Authors:

J Med Chem 2018 10 13;61(20):9004-9029. Epub 2018 Jun 13.

External Innovation Drug Discovery, Global Business Development & Licensing , Sanofi , 13 quai Jules Guesde , 94400 Vitry-sur-Seine , France.

View Article and Find Full Text PDF

October 2018

Strategies for designing GPCR-focused libraries and screening sets.

Authors:

Patrick Jimonet Robert Jäger

Curr Opin Drug Discov Devel 2004 May;7(3):325-33

Chemical Biology GPCRs, High Throughput Medicinal Chemistry, Aventis Pharmaceuticals Inc, 1041 Route 202-206, PO Box 6800, N103B, Bridgewater, NJ 08807-0800, USA.

View Article and Find Full Text PDF

May 2004

9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist.

Authors:

Serge Mignani Georg Andrees Bohme Guillaume Birraux Alain Boireau Patrick Jimonet Dominique Damour Arielle Genevois-Borella Marc Williams Debono Jeremy Pratt Marc Vuilhorgne Florence Wahl Jean Marie Stutzmann

Bioorg Med Chem 2002 May;10(5):1627-37

Aventis Pharma S.A., Centre de Recherche de Paris, Vitry-sur-Seine Cedex, France.

View Article and Find Full Text PDF

May 2002

Publications by authors named "Patrick Jimonet"

New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.

Authors:

Strategies for designing GPCR-focused libraries and screening sets.

Authors:

9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist.

Authors: